GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED
Company Information
- Company Number
- 11721880
- Registered Address
- Gsk Medicines Research Centre, Gunnels Wood Road, Stevenage, United Kingdom, SG1 2NY
- Status
- Active
- Employee Count
- 0
- Turnover
- £170,443,000
- EBITDA
- -£144,786,000
Additional Details
- Company Type
- Private limited Company
- Incorporated On
- 11 December 2018
- Nature of Business
- 96090 - Other service activities not elsewhere classified
- Industries
- Coming Soon
- Region
- East of England
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2025 - 30 Jun 2025 | 29 Jul 2025 | 42 | 50% | 0% | 50% | 0% |
| 01 Jul 2024 - 31 Dec 2024 | 31 Jan 2025 | 39 | 29% | 43% | 28% | 0% |
| 01 Jan 2024 - 30 Jun 2024 | 30 Jul 2024 | 71 | 0% | 0% | 100% | 0% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Qualifying contracts for this entity contain a number of different payment periods: Immediate 30 days 60 days 45 days 30 days and 5th of the following month 60 days and 5th of the following month Payments are made from date of receipt of invoice.
Were there any changes to the standard payment terms in the reporting period?
Standard 30-day terms for SMEs were introduced in place of a previous offer of 30 day terms upon application by the vendor.
Any other information about payment terms
1) Statistics Reported: Intercompany invoices and performance have been excluded from reported statistics as these are generally wholly owned group companies and would distort performance if included. 2) Payment terms for SMEs and 'Paid on Time' monitoring: Preferential payment terms of 30 days are put in place for vendors that are confirmed as SMEs (Small and Medium Enterprises). We closely monitor our KPIs on a weekly basis to ensure that vendors (including SMEs) are paid on time. Corrective actions are taken to remedy any late payment issues where these are within the entity’s control.
Maximum contractual payment period agreed
60
Dispute Resolution Process
We offer our suppliers the following support and service: Enquiries and complaints can be logged through our Helpdesk support system (mail or telephone). Issues are often related to incorrect invoice submission, payment terms are not as per contract, PO details are wrong / nonexistent etc. Key performance metrics are monitored for quality of Helpdesk support. Our Supplier web pages also include details and a link to our Speak Up channels that enable concerns to be raised, including channels managed independently of GSK and the option to do so anonymously, although naturally it helps in resolving matters if we know as much as possible about the issue and complainant. We have invested in Customer Relationship Management (CRM) to ensure effective and independent supplier follow up and support to our suppliers raising issues.
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED is a subsidiary of the global pharmaceutical company GlaxoSmithKline (GSK). The company is primarily involved in the management and protection of GSK's intellectual property assets.
As a part of GSK's sustainability program, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED is committed to responsible and ethical business practices. The company aims to minimize its environmental impact by reducing its carbon footprint and promoting sustainable practices in its operations. It also focuses on employee well-being, diversity and inclusion, and community engagement initiatives.
The company's main products and services include patent portfolio management, patent licensing and enforcement, and intellectual property strategy development. It also provides legal services related to intellectual property matters and supports GSK's research and development efforts by protecting its innovations and discoveries.
The key people in GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED include its current director, David Mark Williams, and its company secretary, Simon Michael Paul Tucker.
Contact information for GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED can be found on GSK's website. The company's registered office address is located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.
In summary, GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.4) LIMITED plays a crucial role in managing and safeguarding GSK's intellectual property assets. The company is committed to sustainable practices, offers a range of products and services related to intellectual property, and is led by experienced and knowledgeable individuals.
